HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
about
Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseasesHistone deacetylase signaling in cardioprotectionMechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersHistone Deacetylases and Cardiometabolic DiseasesSignaling effectors underlying pathologic growth and remodeling of the heartThe Role of ERK1/2 in the Development of Diabetic CardiomyopathyEpigenetic mechanisms in heart development and diseaseEmerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series)HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats.Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.Histone deacetylase activity selectively regulates notch-mediated smooth muscle differentiation in human vascular cells.Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.Minireview: The versatile roles of lysine deacetylases in steroid receptor signalingHDAC9 is an epigenetic repressor of kidney angiotensinogen establishing a sex differenceEarly transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.A blueberry-enriched diet attenuates nephropathy in a rat model of hypertension via reduction in oxidative stress.Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure.Epigenetic mechanisms in heart failure pathogenesisThe Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3.3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.Class I HDAC imaging using [ (3)H]CI-994 autoradiographyPan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cellsTargeting inflammation in heart failure with histone deacetylase inhibitors.Inflammation and oxidative stress are elevated in the brain, blood, and adrenal glands during the progression of post-traumatic stress disorder in a predator exposure animal model.Cardiac HDAC6 catalytic activity is induced in response to chronic hypertensionRoles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction.Non-sirtuin histone deacetylases in the control of cardiac agingAngiotensin II-induced hypertension is modulated by nuclear factor-κBin the paraventricular nucleus.Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure.Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth.Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.Mechanical regulation of epigenetics in vascular biology and pathobiologyKidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.Regulation of the cardiac sodium/bicarbonate cotransporter by angiotensin II: potential Contribution to structural, ionic and electrophysiological myocardial remodelling.
P2860
Q21284678-410A0247-9869-4D6C-A774-B0E54A7722B0Q24568237-0A17AA08-1627-46AB-9A77-75A3B2CFBCCFQ26753129-1517B8F6-D8BB-44F4-86FF-3FC5A0312E80Q26800062-028313CA-2A61-451B-8FC4-D0959F207188Q26825154-0B30B660-8282-44C6-9EA5-0C6EC723BAD5Q28075539-2E8A8E00-6404-4E19-826A-35EDBB849210Q28081134-8D405FF2-92A4-443D-8897-B9E950AF5983Q28082797-0021E659-3A81-4744-AB20-90B1AEB931EFQ29347006-402993FF-2C13-4DFD-83D7-BD672D2EE268Q30277906-61BFB9E8-529B-4DC3-B5D6-4E698EE49DE4Q30424133-CF1F9DB2-410B-4B8A-BF36-DBFA0718EC1DQ30618651-0737FA83-AD4A-4622-91DD-0E7E87FD7BFFQ33632070-1653176D-78F0-4D29-AB2C-02F434FC4F4FQ33742805-46498601-808B-4EFB-909B-92422CCCEDC3Q33853732-333D659B-E274-495E-ABF6-F7F7FC9A214BQ34031250-7415CB14-F0C7-4A26-83B5-23A03A7E7FE3Q34051321-DB6E1029-E138-42F5-B7F2-234877D5AAA7Q34212728-9FF9CBD8-8009-4880-B19A-19CDC0061306Q34277801-ABEF8B55-9BF9-4083-AB7E-84164AE3F1A6Q34296712-A4CFCE53-0894-4BA1-9C2C-21465FBCA77EQ34336500-A96BEA6B-7C18-4EDF-BDB9-4E0A2E06108EQ34353711-436CB5D2-FE8A-4AFA-9429-A9F87188D092Q34515132-EA956D91-F326-4840-9857-A89232B11392Q35016989-B2936F32-FF60-404E-9BDE-838F77352545Q35018476-2795BC97-4917-4E2B-A93A-8939557BFB1CQ35040811-8B9DA1E7-2B1F-43BD-BC40-7EC7BFA977F6Q35517710-030747FA-5C0C-4E28-8670-6A90C926C95BQ35671740-CBA85AAD-C9BC-4842-85B4-68F541B949D1Q35695849-77EED3F4-83B6-4FEB-ABAA-DBE4A099508CQ35707198-A4E6B54A-0B62-45D9-B7D0-5F3C53DC8520Q35947882-F78A7CF0-5C3F-4E07-BAC9-EB7C433440EDQ36212830-988335BA-9594-4081-BBCA-38292A340A55Q36239248-0C81BBAC-0A70-4557-B9F9-1AE6DB6A48E7Q36359544-34974CEC-1BA5-414B-8DFD-EBDAFAD49252Q37041284-C3854634-DDC8-4FE8-B4EE-6B6635FB4076Q37190667-658341D4-B3A5-4536-A81C-A2066599271CQ37239770-63ADF866-9889-498E-9795-82B7B1950F35Q37294107-315C3526-DF36-436A-A450-0BA2C71D18DBQ37907323-DCB60188-1B8B-4CE2-9FB2-3B5E4289C4F7Q38056934-D3DBFF57-8A78-4F29-AB86-5D8C7511F38F
P2860
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@ast
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@en
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@nl
type
label
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@ast
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@en
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@nl
prefLabel
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@ast
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@en
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@nl
P2093
P2860
P1433
P1476
HDAC inhibition attenuates inf ...... ontaneously hypertensive rats.
@en
P2093
Anuradha Guggilam
Carrie M Elks
Jeffrey P Cardinale
Joseph Francis
Nithya Mariappan
Romain Pariaut
Srinivas Sriramula
P2860
P304
P356
10.1161/HYPERTENSIONAHA.110.154567
P407
P577
2010-08-02T00:00:00Z